History

2013

  • December - Completed dosing of CBL0102 Phase 1 trial in Russian Federation
  • August - Dosed first cancer patient with i.v. CBL0137
  • August - Filed IND for CBLB612 in the Russian Federation
  • July - Completed GLP non-irradiated NHP study with entolimod (CBLB502)
  • March - Opened IND for i.v. CBL0137 in the United States

2012

  • October - Dosed first cancer patient with oral CBL0137
  • June - Announced Strong Survival Results for first GLP NHP study with entolimod (CBLB502)
  • March - Dosed first advanced cancer patient with entolimod (CBLB502)
  • April - Opened IND for oral CBL0137 in the Russian Federation

2011

  • October - Opened IND for entolimod oncology studies in the United States
  • September - Launched Panacela Labs, Inc.
  • August - Science Translational Medicine published breakthrough paper on mechanisms of action of Curaxins

2010

  • November - Dosed first advanced cancer patient with CBL0102 in Russian Federation
  • November - Granted Orphan Drug status designation by FDA for entolimod (CBLB502)
  • September - Received second major development and conditional purchase contract for entolimod (CBLB502) from CBMS/DoD
  • July - Granted Fast Track status designation by FDA for entolimod (CBLB502)
  • April - Launched Incuron, LLC
  • January - Received first European patent for entolimod (CBLB502)
  • January - Received first U.S. patent for entolimod (CBLB502)

2009

  • November - Entered licensing agreement for CBLB612 with Zhejiang Hisun Pharmaceutical Co. Ltd. In China
  • September - Awarded prestigious Grand Opportunities grant from NIAID/NIH

2008

  • December - Completed first Phase II study of CBL0102 in Hormone Refractory Cancer Patients
  • October - Dosed first healthy volunteer in initial safety study with entolimod (CBLB502)
  • September - Awarded first major development contract for entolimod (CBLB502) from BARDA/DHHS
  • August - Opened IND for entolimod’s (CBLB502) biodefense indication
  • April - Science magazine published breakthrough paper on entolimod (CBLB502)'s radioprotective activity
  • March - Awarded first major development contract for entolimod (CBLB502) from CBMS/DoD

2007

  • November - Completed first cGMP manufacturing run for entolimod (CBLB502)
  • June - Formed strategic alliance with Roswell Park Cancer Institute and relocated to Buffalo, NY

2006

  • June - IPO on NASDAQ
  • May - Opened IND for CBL0102 in US
  • 2004-2006 - Received significant Small Business Innovation Research grant and contract funding from NASA and NIH

2004

  • August - Established Cooperative Research and Development Agreement with Armed Forces Radiobiology Research Institute

2003

  • June - CBLI founded in partnership with Cleveland Clinic
You are now leaving this website. If you would like to continue, click Continue.
CancelContinue